‘Europe DTC Laboratory Testing Market’ by Application (Genetic Testing {Ancestry, Carrier Status, Disease Risk [Cancer, Neurological, Cardiac]}, Diabetes, Thyroid, STD, Routine, CBC), Sample Type (Saliva, Urine, Blood) - Forecast to 2030. According to this latest publication from Meticulous Research®, the Europe direct-to-consumer laboratory testing market is projected to reach $1.59 billion by 2030, at a CAGR of 10.8% from 2023 to 2030. The growth of the Europe direct-to-consumer laboratory testing market is driven by several factors, including the rising incidence of chronic diseases & sexually transmitted diseases, increasing awareness about personal health management, benefits of DTC laboratory testing such as high convenience, affordability, & accessibility, increasing cost of healthcare, increasing consumer awareness about ancestry/genealogy testing, and the rising elderly population. Factors such as the growing adoption of telehealth, expansion in emerging economies, and the increasing penetration of pharmacogenomic testing in DTC laboratory testing are some opportunities that would help grow the market. To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/europe-dtc-laboratory-testing-market-5641 Genetic data privacy concerns, misinterpretation of test results, and lack of professional medical counselling could be challenges for the Europe direct-to-consumer laboratory testing market. However, the sample integrity and interference issues, regulatory concerns, lack of reimbursement, and limited test portfolio compared to conventional laboratory testing restrain the market's growth. The Europe direct-to-consumer laboratory testing market is segmented by Application (Genetic Testing [Ancestry/Genealogy, Disease/Risk Assessment {Cancer, Cardiovascular Diseases, Neurological Diseases, & Other Applications}, Carrier Status, Other Genetic Tests], Diabetes Testing, Routine Clinical Testing, Thyroid Function Testing, Sexually Transmitted Disease Testing, and Other Applications), Sample Type (Blood, Saliva, Urine, and Other Samples) and Geography. The study also evaluates industry competitors and analyzes the regional and country-level markets. Request for Sample: https://www.meticulousresearch.com/request-sample-report/cp_id=5641 Among applications, in 2023, the genetic testing segment is expected to account for the largest share of the market. The large share of the segment is attributed to the rising appeal of DTC genetic testing to explore information regarding family health history and disease risk assessment testing, the launch of new DTC genetic tests for new applications, and increasing interest among people in developed countries regarding their ancestry and lineage. Among sample types, the blood segment is expected to account for the largest share of the market. The large share of the segment is attributed to the benefits of blood samples, such as the high reliability of results, the wide range of test options available, and the convenience of at-home blood collection services. Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5641 This research report analyzes major European geographies: Germany, the U.K., France, Spain, Italy, Switzerland, Netherlands, Belgium, Denmark, Ireland, and the Rest of Europe. In 2023, the U.K. is expected to account for the largest share of the Europe direct-to-consumer laboratory testing market. U.K.’s major market share is attributed to increased consumer awareness, high disposable income, and the rising incidence of chronic & sexually transmitted diseases. Request for Customization: https://www.meticulousresearch.com/request-customization/cp_id=5641 Key Players: The key players profiled in the Europe direct-to-consumer laboratory testing market report are LetsGetChecked, Inc. (U.S.), Laboratoire CERBA (France), 23andMe Holding Co. (U.S.), Medichecks.com Ltd. (U.K.), Cerascreen Biotech LLC (U.K.), Living DNA Ltd (U.K.), SelfDiagnostics Deutschland GmbH (Germany), SYNLAB International GmbH (Germany), Natrix S.r.l. (Italy), and Mainz Biomed Germany GmbH (Germany).